Research analysts at Northland Securities assumed coverage on shares of Nephros (NASDAQ:NEPH – Get Free Report) in a note issued to investors on Friday. The firm set a “market perform” rating and a $4.00 price target on the stock. Northland Securities’ price objective suggests a potential upside of 6.38% from the company’s current price.
Separately, Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.00.
Check Out Our Latest Stock Analysis on Nephros
Nephros Trading Up 3.3%
Nephros (NASDAQ:NEPH – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $5.21 million during the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a return on equity of 7.66% and a net margin of 4.06%.
Institutional Trading of Nephros
A number of large investors have recently made changes to their positions in NEPH. Kestra Advisory Services LLC acquired a new position in Nephros in the 4th quarter valued at about $29,000. Heron Bay Capital Management purchased a new stake in Nephros in the 4th quarter worth approximately $66,000. Dimensional Fund Advisors LP acquired a new position in Nephros in the 3rd quarter valued at $64,000. Citadel Advisors LLC lifted its stake in shares of Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after purchasing an additional 4,655 shares during the period. Finally, XTX Topco Ltd lifted its stake in shares of Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after purchasing an additional 7,062 shares during the period. Institutional investors and hedge funds own 41.10% of the company’s stock.
About Nephros
Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.
The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.
Recommended Stories
- Five stocks we like better than Nephros
- The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet
- Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.
